PTC Therapeutics (PTCT) Q4 2025 earnings summary

Executive summary

• Achieved initial global approvals and strong launch of Sephience for PKU, with broad uptake across all patient segments and age groups in the U.S., E.U., Japan, Brazil, and other countries within months of approval.

• Full-year 2025 product and royalty revenue reached $831 million, surpassing guidance, with Sephience generating $111 million since launch.

• Collaboration and license revenue of $998.4 million in 2025, mainly from the votoplam agreement with Novartis.

• Monetized remaining Evrysdi royalty for $240 million upfront and up to $60 million in milestones, ending 2025 with $1.95 billion in cash.

• Advanced R&D pipeline with positive phase II PIVOT-HD results for Votoplam and progress in RNA splicing and inflammation platforms.

Financial highlights

• Total revenues for 2025 were $1.73 billion, up from $806.8 million in 2024.

• Q4 2025 net product and royalty revenue: $263 million; full-year 2025: $831 million, exceeding guidance of $750–$800 million.

• Sephience generated $92 million in Q4 and $111 million since launch in 2025.

• DMD franchise revenue in Q4: $66 million; full-year DMD franchise: $382 million.

• Net income for 2025 was $682.6 million, compared to a net loss of $363.3 million in 2024.

Outlook and guidance

• 2026 total product revenue guidance is $700–$800 million, a 19–36% increase from 2025, with Sephience as the main driver.

• 2026 expense guidance: GAAP R&D and SG&A $775–$815 million; non-GAAP $680–$720 million, excluding $95 million in stock-based compensation.

• Excludes Evrysdi royalty revenue due to royalty sale.

• Expect commercial patients in 20–30 countries by year-end 2026, with significant international expansion.